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ABSTRACT  
The intact absorption of a β-casein peptide, HLPLP, into rat blood circulation 
after oral administration was recently demonstrated. In addition to the parent 
peptide, several derived fragments were detected in rat plasma. The aim of the 
present work is to elucidate whether these fragments retain antihypertensive 
activity and if their activity is mediated by angiotensin-converting-enzyme 
inhibition. The penta-peptide was incubated in rat plasma in order to identify 
and quantify the fragments generated by the action of plasmatic peptidases on 
HLPLP, using tandem mass spectrometry. Peptides HLPL, LPLP and HLP were 
generated within seconds of incubation. The parent peptide, HLPLP, and all 
possible derived peptides showed potent antihypertensive activity in 
spontaneously hypertensive rats and caused inhibition of vascular contraction 
elicited by angiotensin-I. It can be concluded that the antihypertensive effect of 
HLPLP can be produced by the concomitant action of the parent peptide and 
several novel derived fragments. 
Keywords: Antihypertensive peptides/ in vivo active form/ plasma peptidases/ 
SHR/ tandem mass spectrometry. 
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1.Introduction 
In recent years, the evaluation of changes that bioactive peptides undergo in 
the organism after ingestion has gained importance, since the administered 
form and the active form can be different. The identification of the in vivo active 
form will allow a better establishment of the mechanism of action, and of the 
cause/effect relationship for bioactive peptides, which are needed to support a 
health claim. These changes take place during gastrointestinal digestion and 
subsequent absorption, distribution, metabolism and elimination (ADME). Upon 
gastrointestinal digestion, food peptides can resist or can undergo hydrolysis, 
and this may cause a loss of their activity or, on the contrary, the release of the 
active sequence. For instance, the active form of the peptide β-casein f(169-
175) is generated after losing the C-terminal glutamine residue during intestinal 
digestion (Maeno, Yamamoto, & Takano, 1996). Similarly, an antihypertensive 
peptide from a casein hydrolysate, αs1-casein f(90-94) RYLGY, was partly 
degraded when subjected to simulated gastrointestinal digestion, giving rise to 
smaller peptides. Some of these peptide fragments thereof, RYLG, RY, and 
YLGY retained antihypertensive activity while YLG did not exert any 
antihypertensive effect (Contreras, Sánchez, Sevilla, Recio, & Amigo, 2013). 
Once the stability of peptides to digestion is ensured, bioavailability 
studies need to be conducted, in order to determine the accessibility of potential 
biologically active peptides in the organism (Foltz, van der Pijl, & Duchateau, 
2010; Picariello et al., 2013). The assessment of the peptide stability to soluble 
plasma peptidases once they are absorbed can play an important role on the 
exhibition of its biological effect (Vermeirssen, Van Camp, & Verstraete, 2004; 
Miner-Williams, Stevens, Moughan, 2014). In this regard, mass spectrometry 
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(MS)-based techniques have permitted the development of sensitive methods to 
detect and quantify small changes of peptides in plasma samples, reaching 
detection limits in the picogram range (van Platerink, Janssen, Horsten & 
Haverkamp, 2006). In addition, these techniques allow to follow the peptide 
biotransformations which can take place in the organism. 
The peptide LHLPLP, f(133-138) from β-casein, present in an 
antihypertensive fermented milk, was identified as one of the sequences that 
most contributed to the biological effect caused by this fermented milk, and this 
product exerted angiotensin-converting-enzyme (ACE)-inhibitory and 
antihypertensive activity after acute and long-term oral administration (Quirós et 
al., 2007; Miguel et al., 2005). This sequence was reported to be resistant to 
gastrointestinal digestion (Quirós, Contreras, Ramos, Amigo & Recio, 2009). 
However, when incubated with Caco-2 cells, the hexapeptide was partly 
degraded by brush border-like enzymes expressed by these cells, releasing the 
peptide HLPLP, f(134-138), which underwent epithelial transport across the 
Caco-2 cell monolayer (Quirós, Dávalos, Lasunción, Ramos & Recio, 2008). 
Recently, β-casein f(133-138), HLPLP has been found in rat blood circulation 
after its oral administration at 40 mg/kg body weight (absorption ratio of 5.18%) 
(Sánchez-Rivera et al., 2014a). In addition to the parent peptide, several 
derived fragments (LPLP and HLPL) were detected after both, intravenous and 
oral administration of the penta-peptide HLPLP. However, whether the derived 
fragments released in plasma could retain any biological activity remained to be 
demonstrated. 
The aim of this study is to determine if any of the fragments that had 
been previously demonstrated to be released in vivo from the penta-peptide 
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HLPLP retain antihypertensive activity. To reach this objective, in a preliminary 
experiment, the fragments generated during incubation of the peptide in rat 
blood plasma were quantitatively analyzed by ultra-high performance liquid 
chromatography (UPLC) coupled on line to a quadrupole-time-of-flight (Q-TOF) 
analyzer. Identified fragments were chemically synthesized and their 
antihypertensive effect was evaluated in spontaneously hypertensive rats (SHR) 
after single oral administration. In addition, their ability to inhibit ACE was 
assessed in isolated aorta rings. 
2. Materials and methods 
2.1 Peptide synthesis and standard solution preparation.  
Peptides were synthesized in-house by conventional fluorenyl-methoxy-
carbonyl chloride (fmoc) solid-phase method, using a 431A peptide synthesizer 
(Applied Biosystems Inc. Überlingen, Germany). The synthesized peptides 
corresponded to β-casein sequences: HLPLP f(134-138), HLPL, f(134-137), 
HLP, f(134-136), LPLP, f(135-138), and LPL, f(135-137). Peptide PLP, β-casein 
f(136-138), was purchased from SynPeptide CO, LDT (Shanghai, China). Their 
purities were above 93%, calculated by RP-HPLC-UV-MS. All other chemicals 
were of the highest quality grade. The standard curves of HLPLP, HLPL, LPLP 
and HLP in plasma where prepared as previously described (Sánchez-Rivera et 
al., 2014a). Briefly, each synthetic peptide diluted in Milli-Q water was added to 
plasma to reach final peptide concentrations from 2.5 ng mL-1 to 20 µg mL-1. 
Immediately after, 40 µL of trifluoroacetic acid (TFA) solution (10%, v/v) were 
added, followed by heat treatment up to 99°C for 2 min. After centrifugation 
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(8500 × g, 30 min), the supernatant was purified using mixed mode action 
exchange cartridges (Bond Elut Plexa PCX, 60 mg, 1 ml, Agilent, Santa Clara). 
2.2 Incubation of peptide β-casein f(134-138) in rat plasma.  
The peptide HLPLP, β-casein f(134-138) was incubated in rat control 
plasma obtained from female Wistar rats (250-300 g). The rats were 
anaesthetized using pentobarbital at intraperitoneal dose of 60 mg kg-1 body 
weight and the blood was extracted by cardiac puncture (5 mL per rat), with 5 
mL 23G syringe. The blood was introduced in a lithium-heparin 9 mL tube, and 
centrifuged at 3600 rpm for 20 min at 4ºC. The supernatant was collected and 
frozen at -20ºC until use. Plasma was mixed 5:1 with the peptide aqueous 
solution to reach a final concentration of 0.06 mg mL-1 (0.10 mM). This mixture 
was kept at 37ºC during the experiment in a thermally controlled water bath 
(AQUAline AL25, LAUDA WOBSER, GmbH & Co., Postfach, Germany). 
Sampling was done at 5, 30, 60, 120 and 240 min after peptide addition to the 
plasma, and also an aliquot was taken just after the peptide was spiked in 
plasma and vortexed for 10 seconds (T0). The incubation was stopped using 
TFA (10%, v/v) and the plasma samples were treated as described above. 
2.3 UPLC-Q-TOF analyses.  
The analyses of the plasma samples were performed on an UPLC from 
Waters (Milford, MA, USA), coupled to a MicroTOF-QII instrument (Bruker 
Daltonik, Germany). These analyses were carried out as described by Sánchez-
Rivera et al. (2014a) with some modifications. The pseudo-selected ion 
monitoring (SRM) method was set up to fragment the following parent ions, with 
mass-to-charge ratio (m/z) of 576.34, 439.28, 479.29, 366.21, 342.23, and 
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326.20, which corresponded to the sequences HLPLP, LPLP, HLPL, HLP, LPL 
and PLP, respectively. The amount of peptide fragments at different incubation 
times was quantified by the extraction of their corresponding molecular ions 
(m/z) and expressed as concentration (μM) by the use of a standard curve for 
each peptide. 
2.4 Pharmacological activity assays. 
All the animal trials were carried out according to the European Union 
guidelines for the ethical care and use of laboratory animals (European 
Directive 2010/63/EU). 15 to 17-week old spontaneously hypertensive rats 
(SHR) were purchased from Elevage Janvier (Le Genest, Saint Isle, France). 
The animals were housed in groups of three rats and kept at 23ºC with 12 h 
light/dark cycles in the Animal Experimentation Service of Salamanca University 
(NPAE SA001). Standard food (Global Diet 2014, Harlan, France) and water 
were available ad libitum. 
2.4.1 Antihypertensive activity assays in SHR. 
To determine the antihypertensive activity, the synthesized peptides 
dissolved in ultrapure water were orally administered using an oesophageal 
cannula, at a single dose of 7 mg kg-1 body weight, and the control group 
received the same volume of water. The animals were deprived of solid food 
diet 12 h before experiments, only having access to sucrose (80 g L-1) and NaCl 
(2 g L-1) solution. The systolic blood pressure (SBP) was measured as 
previously described (Sánchez et al., 2011), using the CODA tail-cuff blood 
pressure system (Kent Scientific, Torrington, CT, USA). The measurement of 
SBP was performed before peptide administration to estimate the basal blood 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
8 
 
pressure, which was 155 mmHg for SBP, and after administration thereof at 2, 
4, 6, 8 and 24 h. The changes in the measurement of SBP were expressed as 
mmHg. 
2.4.2 ACE-inhibition assays in aorta rings. 
To determine ACE inhibition, isolated thoracic aorta rings were mounted 
in organ bath with Krebs solution at 37ºC aerated with carbogen as described 
elsewhere (Sánchez et al., 2011). After an equilibration period for 1 h at a 
resting tension of 2 g, the functionality of the rings was tested with a 120 mM 
solution of KCl. After that, rings were incubated with different peptides (HLPLP, 
LPLP, HLPL or HLP) at a dose 10-4 M (100 μM), for 30 min, and the contractile 
response to Ang I (10-7 M) was evaluated. Captopril (10-6 M) was used as 
positive control. 
2.5 Statistical analysis. 
The mean values are expressed with the standard error of mean (SEM). 
The effect of each administered peptide over time and versus the control 
(water) was recorded. Two-way analysis of variance (ANOVA), using GraphPad 
Prism 5.0 (GraphPad software Inc., San Diego, USA) was performed. 
Bonferroni post-test was applied to establish the significant differences between 
the peptides and the control. Contractile responses to Ang I were expressed as 
mg of contraction and statistical analysis was made using one way ANOVA 
comparing responses to Ang I in absence and presence of the peptides during 
the incubation period. Differences were considered significant at P ≤ 0.05. 
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3. Results 
3.1 Hydrolysis of β-casein f(133-138), HLPLP, by plasma peptidases. 
To evaluate the resistance of β-casein f(133-138) HLPLP to plasma 
peptidases over time and to identify the formation of derived fragments, the 
penta-peptide was incubated in rat plasma for 4 h. Peptide was dissolved in 
plasma at a concentration of 0.06 mg mL-1 selected on the basis of previous in 
vivo experiments where the peptide was intravenously administered to rats 
(Sánchez-Rivera et al., 2014a). Blank plasma was previously analyzed to 
confirm that neither HLPLP nor derived fragments were naturally present in 
plasma before these experiments (data not shown). A disappearance of 20% for 
HLPLP was observed from time zero to 5 min (Figure 1a); although from this 
point to 30 min, 6-fold decrease was observed. Then, plasma peptidases 
caused a pronounced depletion on its concentration from 30 to 60 min of 
incubation (10-fold decrease, from 0.9 to 0.09 μM). Nevertheless, the peptide 
was detected until 240 min. The formation of all possible tetra- and tri-peptides 
was monitored by pseudo-SRM and three derived fragments were identified and 
quantified during incubation in plasma, i.e., LPLP, HLPL and HLP. The release 
of the peptide fragments occurred rapidly and the two tetra-peptides, HLPL 
(Figure 1b) and LPLP (Figure 1c) were detected in the first sample withdrawn 
from the incubation (time zero). These tetra-peptides suffered a decrease from 
5 to 30 min, to 7,05% and 1,61%, respectively, of the initial amount detected in 
plasma. The first one, resisted during 60 min of incubation, however the latter 
one, was observed up to 120 min. The tri-peptide HLP (Figure 1d) was also 
detected at time zero, and increased significantly during the first 5 min of 
incubation in plasma, keeping a rising trend until 60 min; to finally suffer a 
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pronounced decrease, although it was still detected at 240 min of incubation. 
The concentration of HLPLP quantified at time zero was only 5.8% of the total 
amount initially added to plasma. At this point, its derived fragments LPLP, 
HLPL and HLP represented 24%, 0.5% and 7.8%, respectively, of the initial 
amount of HLPLP spiked into the plasma. These results sum up to 38.1% of the 
reference amount of HLPLP added to plasma. Thus, other peptide fragments, 
such as, LPL and PLP, and free amino acids might be released by the action of 
plasma peptidases, although the limitation of the MS-based technique to identify 
short peptides in plasma may have precluded their detection. 
3.2 Evaluation of the antihypertensive activity in SHR.  
In order to assess the antihypertensive activity of the fragments released 
from HLPLP, the parent peptide, and all possible derived tetra- and tri-peptides 
were chemically synthesized. Figure 2 shows the antihypertensive effect of the 
different β-casein peptides, orally administered to SHR at 7 mg kg-1 body 
weight. This dose had been previously assayed for peptide HLPLP in SHR and 
produced a significant SBP decrease (Miguel, Gómez-Ruiz, Recio, & 
Aleixandre, 2010). The administration of HLPLP and its derived peptide 
fragments led to different behaviours in regard to the trend of SBP decrease. 
The parent peptide, HLPLP, (Figure 2a), showed a maximum decrease of the 
SBP at 2 h post-administration (21.1 ± 3.4 mmHg) and subsequent recovery 
occurred from this point. However, the two tetra–peptides, HLPL and LPLP 
(Figures 2b and 2c, respectively) caused a reduction on SBP that reached its 
maximum 4 h after administration (19.4 ± 3.8, and 16.2 ± 3.8 mmHg, 
respectively). The administration of the tri-peptides HLP, LPL and PLP (Figures 
2d, 2e and 2f, respectively) to SHR led to a delay on the decrease of SBP 
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compared to the previous ones. HLP and LPL showed a maximum, peak of 
SBP reduction 6h after administration (15.2 ± 1.4 and 22.0 ± 2.5 mmHg, 
respectively). Finally, the administration of PLP induced the most effective SBP 
decrease in terms of endurance. This peptide caused a gradual drop of SBP 
values that reached its maximum at 8 h post-administration (21.2 ± 3.4 mmHg). 
The long-lasting effect of this peptide, led to a slow rate of recovery. At 24 h, 
significant differences with the control on the reduction of SBP were still 
observed.  
3.3 ACE inhibition in aortic rings.  
The response of angiotensin I in isolated aortic rings was assessed after 
incubation with the precursor peptide and the derived-fragments identified in 
plasma. Angiotensin-I is converted to Angiotensin-II by tissue ACE activity, 
resulting in a contractile response. Figure 3 shows that the contractile response 
to Angiotensin-I (780 +/- 100 mg) was significantly reduced in the presence of 
the peptides tested at 10-4 M. The highest reduction (44% of the control) was 
achieved with HLPLP, but no significant differences were observed among all 
tested peptides. However, the reduction induced by the ACE inhibitor captopril 
(82% of the control, at 10-6 M) was more efficient than that observed for HLPLP. 
4. Discussion 
Most studies on food-derived antihypertensive peptides associate the 
orally administered sequence with a given effect, although it is known that 
peptides might suffer hydrolysis during digestion, absorption and, if they reach 
circulation, further degradation by plasmatic peptidases. The region from β-
casein 130-140 has been shown to be especially resistant to digestion and 
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peptides comprised in this region have been found by us and others after 
simulated gastrointestinal digestion of dairy products (Robert, Razaname, 
Mutter & Juillerat, 2004; Dupont et al., 2010; Picariello et al., 2013; Sánchez-
Rivera et al., 2014b) and in human jejunal aspirates (Boutrou et al., 2013). The 
evidence of the absorption of the antihypertensive penta-peptide HLPLP, f(134-
138), that can be formed after milk digestion represents a step forward in the 
study of bioavailability of food derived peptides. The kinetic parameters of 
absorption and elimination have revealed that HLPLP is rapidly absorbed and 
the oral bioavailability has been calculated on the basis of HLPLP concentration 
in plasma. Interestingly, it was observed that this penta-peptide was further 
hydrolyzed into smaller fragments in vivo, and the kinetic parameters for the 
biotransformed derived fragments, LPLP and HLPL, were also calculated, 
showing elimination half-life values of 8.38 and 10.9 min, respectively 
(Sánchez-Rivera et al., 2014a), although the formation of other biotransformed 
fragments could not be excluded. The route of the formation of these derived 
fragments and if they could exert antihypertensive activity remained to be 
ascertained. 
In this work, the plasma incubation permitted to assure that the penta-
peptide is degraded by the action of soluble blood plasma peptidases giving rise 
to, at least, two tetra-peptides and one tri-peptide, LPLP, HLPL and HLP. 
However, other peptide fragments were probably formed, known the limitation 
of MS for short peptides and as revealed by the mass balance. Two of the 
peptide fragments (LPLP and HLPL) identified in this study during in vitro 
incubation of the penta-peptide were coincident with those found in vivo after 
oral and intravenous administration of HLPLP in rats (Sánchez-Rivera et al., 
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2014a). Thus, one of the routes of degradation of HLPLP in vivo probably 
involved plasma peptidases once the peptide reached blood circulation. The 
initial concentration of HLPLP detected in plasma after incubation was under 
the expected value, due to its fast degradation into its derived fragments. The 
increase in concentration undergone by HLP during incubation in plasma from 5 
to 60 min coincides with the decrease monitored for HLPL and HLPLP. These 
results could indicate the formation of the tri-peptide from both the penta- and 
tetra-peptide, by the action of plasma peptidases. Moreover, the concentration 
calculated for HLPL is lower than that of LPLP and HLP, suggesting that HLPL 
could be further hydrolyzed into HLP. The concentrations of LPLP and HLP 
were higher than that of the precursor peptide (6 and 5-fold, respectively), 
showing the rapid and extensive hydrolysis of the penta-peptide into smaller 
peptide fragments even a few seconds after incubation (time zero). Similar 
results for the peptide fragment LPLP, were reported in vivo after administration 
of HLPLP to rats, where this tetra-peptide was found in plasma at higher 
concentration compared to its precursor (Sánchez-Rivera et al., 2014a). This 
immediate degradation of HLPLP is consistent with that observed for 
Angiotensin II in plasma, which occurred within seconds (Moskiwitz, 2003), and 
also with the rapid degradation reported for other dairy peptides such as, 
Lactokinin [β-lactoglobulin f(142-148)] in human serum (Walsh et al., 2004).  
In view of the results, the main circulating peptide in blood after HLPLP 
ingestion could be LPLP, which has shown a significant antihypertensive effect, 
although less acute than the observed in the pentapeptide. For antihypertensive 
peptides where absorption has been demonstrated, the required plasma 
concentration known to exert the biological effect was approximately 1000-fold 
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higher than the plasma concentrations reported. This was the case of the 
casein–derived tripeptide IPP in a clinical study involving ingestion of a 
lactotripeptide enriched yogurt beverage. Maximal plasma concentrations were 
in the picomolar level and an elimination half-life of 30 min was determined 
(Folz, Meynen, Bianco, van Platerink, Koning, & Kloek., 2007). In a 
pharmacokinetic study in piglets, where intragastric administration of synthetic 
IPP, LPP and VPP was conducted, the calculated bioavailability was 0.1% and 
the determined elimination half-lives ranged from 5 to 20 min (van der Pijl, Kies, 
Ten Have, Duchateau, & Deutz, 2008). The present work supports that plasma 
concentration of peptides might be underestimated due to biotransformation of 
the peptide into other active fragments. In contrast, for the dipeptide VY 
ingested in an enriched beverage, plasma concentrations in the nanomolar level 
were reached but a long half-life of 3.1 h was observed (Matsui, Tamaya, Seki, 
Osajima, Matsumoto, & Kawasaki, 2002). These values suggest an impaired 
degradation of the peptide. 
With regard to the observed effects for the different peptides, it has to be 
pointed out that many biologically active peptides are protected from general 
proteolytic degradation by evolutionary conserved prolines. Interestingly, the 
PLP sequence was one of the common motifs employed by Juillerat-Jeanneret, 
Robert, & Juillerat (2011) to identify inhibitors of prolyl-specific proteases 
comprised in the αs1- and β-casein sequences. The high antihypertensive 
potency shown by peptide PLP is consistent with its structure, which is 
favorable to bind and inhibit ACE (Quirós et al., 2009). In addition, it could 
inhibit prolyl-proteases activity which might explain the endurance of the effect 
exerted by this tri-peptide. 
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In view of the results obtained on aortic rings, it is proved that the 
antihypertensive effect of peptide HLPLP and those produced by the action of 
blood plasma peptidases is due, at least in part, to its ability to inhibit ACE. 
These results are in agreement with previous studies where the peptide HLPLP 
showed antihypertensive activity and inhibited ACE activity in vitro (IC50 21 μM) 
(Hernández-Ledesma, Quirós, Amigo, & Recio, 2007). However, the effect 
found for and LPLP on aortic rings at 100 μM was higher than that expected 
based on the reported in vitro ACE-inhibitory activity (IC50 720 μM, respectively) 
(Kohmura, Nio, Kubo, Minoshima, Munekata, & Ariyoshi, 1989). Similarly, IPP 
and VPP have been reported as ACE inhibitors in vitro with an IC50 value at 
micromolar level (Nakamura, Yamamoto, Sakai & Takano, 1995). In addition, 
these tri-peptides have also shown ACE-inhibitory activity in mesenteric artery 
rings after 24h of incubation with the tri-peptides (Jäkälä, Jauhiainen, Korpela & 
Vapaatalo, 2009). 
 
5.Conclusions 
The incubation of the antihypertensive peptide β-casein f(134-138) 
HLPLP in rat blood plasma permitted the identification of novel derived 
fragments (HLPL, LPLP and HLP), which may be physiologically relevant in 
respect of the antihypertensive effect. These peptide fragments are coincident 
with those previously found in vivo. Some of the fragments found in this study, 
such f(134-136) HLP, were detected until 240 min of incubation time. All 
possible peptide-fragments derived from HLPLP retained antihypertensive 
activity when orally administered to SHR. Our results after oral administration 
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have allowed the identification of new active β-casein tri-peptides, which could 
be produced by fermentation or enzymatic hydrolysis as enrichment strategies. 
From all the peptide fragments, the tri-peptide PLP showed the longest lasting 
antihypertensive effect which was significant up to 24 h after administration. The 
incubation of HLPLP in plasma, which was known to be absorbed intact into 
circulation, was a good in vitro approach to follow its further degradation by 
plasmatic peptidases, since the identified fragments were in accordance to 
those found in vivo after administration of HLPLP to rats. These results should 
be taken into account in the overall physiological effect of the penta-peptide 
HLPLP. Inhibition of ACE is involved in the mechanism of antihypertensive 
activity of these peptides, although further studies should be conducted to 
explore if other possible mechanisms could be concerned. 
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Figure Captions 
 
Figure 1. Concentrations (µM) of the peptides HLPLP (a), HLPL (b), LPLP (c) 
and HLP (d) identified during the incubation of the penta-peptide in plasma. 
Mean values ± SEM (n=3).  
 
Figure 2. Systolic blood pressure decrease (Δ) caused in spontaneously 
hypertensive rats after administration of water (*), or 7 mg kg-1 of body weight of 
HLPLP (a), HLPL (b), LPLP (c), HLP (d), LPL (e) and PLP (f). Mean values ± 
SEM (n=5-6) are represented. Statistical differences were found at p≤0.05 (*), 
p≤0.01 (**) and p≤ 0.001(***). 
 
Figure 3. Responses to Angiotensin I (Ang I, 10-7 M) in aortic rings in absence 
(control) and presence of the peptides (10-4 M) or captopril (10-6 M) after the 
incubation for 30 min. Mean values ± SEM (n=5-10) are represented. * 
p≤0.05,*** p≤0.001 versus control. 
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Highlights 
Fragments generated by plasmatic peptidases on peptide HLPLP have been 
identified 
Three peptides coincide with those found in vivo after HLPLP administration to 
rats 
All possible derived peptides from HLPLP show potent antihypertensive activity 
The peptides caused inhibition of vascular contraction elicited by angiotensin-I 
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